June 6, 2025
As the share pricing loaded train navigates a narrow path to the upside
Recent economic data has pointed to a slowdown in the U.S., raising questions about the impact of the multi-front tariff negotiations and the next steps for the Fed
Breaking: U.S. payrolls climbed 139,000 in May, the Bureau of Labor Statistics reported Friday, above the forecast of 125,000 for the month but less than the downwardly revised 147,000 in April. The unemployment rate was unchanged at 4.2%.
TGIF
Pre-open Indications: 3 Positive and 1 Sell into Strength
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
June 4, 2025
Newest ...
6/4/25 ... The Harvard Apparatus RT (OTCQB: HRGN) Chronicles:
Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)???
No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations
June 6, 2025
Even I thought, “uncle algo and his electronic dwarfs” would swoop-in
The econs nonfarm payrolls report came in better than expected spicing the market
Waiting for news from ASCO – to keep the sector’s upside viable
Always be vigilant and in-the-know concerning your portfolio … why you need RMi!
Never leave an investor uninformed!
June 4, 2025
Newest ... 6/4/25 ... The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.
May 13, 2025
SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
June 6, 2025
RegMed Investors (RMi) Closing Bell: surprise, a positive open and close
June 6, 2025
RegMed Investors’ (RMi) pre-open: econs set the tone
June 5, 2025
RegMed Investors (RMi) Closing Bell: Signs of hesitancy in share pricing activity
June 5, 2025
RegMed Investors’ (RMi) pre-open: hold-on the railings
June 4, 2025
RegMed Investors (RMi) Closing Bell: Gauging sector breadth
June 4, 2025
RegMed Investors’ (RMi) pre-open: Don’t hold your breath
June 3, 2025
RegMed Investors (RMi) Closing Bell: who and what is driving gains
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
